Mingdu Zhiyun Completes Series C Financing of Several Hundred Million RMB to Empower Digital Transformation in the Life Sciences Industry

VCBeat has learned at the earliest opportunity that a digital transformation service provider in the life sciences sectorZhejiang Mingdu Intelligent Control Technology Co., Ltd. (hereinafter referred to as “Mingdu Zhijun”)Officially announced the completion of a C-round financing amounting to hundreds of millions of yuan, led bySCGC Leads Investment, China Merchants HealthAdditional Investment,Index CapitalServe as the exclusive financial advisor.

Ge Yafei, Founder and Chairman of Mingdu Intelligent CloudThe completion of this financing round not only demonstrates investors’ strong confidence in the broad prospects of digital transformation within China’s life sciences sector, but also reflects their high recognition of Mingdu Intelligent Cloud’s intelligent digital products, technological innovation capabilities, team spirit, and global vision in the life sciences field. Investors believe that Mingdu Intelligent Cloud is well-positioned to lead innovation in the digital and intelligent transformation of the pharmaceutical industry. Mingdu Intelligent Cloud will continue to deepen its strategic layout in the life sciences sector, driving and accelerating the digital transformation of the pharmaceutical industry.

Wang Fei, Chief Operating Officer of Mingdu Zhiyunstated that the company will continue to adhere to a customer-success-centric approach, continuously enhancing its product capabilities and service delivery; accelerate the deep integration of AI with its products, and build next-generation AI-driven lightweight solutions on a unified digital foundation to adapt to complex and evolving application scenarios, as well as the trends toward enterprise groupization and globalization.

Mingdu Intelligent Cloud, established in 2017, is a leading digital transformation service provider in the life sciences sector in China. Anchored by R&D and manufacturing in the era of Pharmaceutical Industry 4.0, it has built an intelligent digital technology platform that synergizes “Digital Laboratories” and “Digital Factories,” empowering pharmaceutical companies to achieve comprehensive digital transformation in R&D, production, future factories, and quality control.

To date, Mingdu Intelligent Cloud has servedOver 350 pharmaceutical company clients, including well-known domestic pharmaceutical companies and research institutions such as Shanghai Pharmaceuticals Group, Livzon Pharmaceutical Group, Sinopharm Group, China Resources Sanjiu, Walvax Biotechnology, Wantai BioPharm, Humanwell Healthcare, and Tianjin Institute of Pharmaceutical Research.

Amid domestic healthcare reforms, the advancement of government-led volume-based procurement, and the trend toward globalization, the pharmaceutical industry must address increasingly fierce challenges by accelerating product launches and reducing operational costs. This has spurred digital opportunities for vertical suppliers across research and development, manufacturing, and distribution.

The digitalization of the pharmaceutical industry currently boasts a market potential worth hundreds of billions of yuan. However, the digital transformation of domestic Chinese pharmaceutical companies is still in its infancy, lacking mature models for such transformation. Statistics show that 70% of China’s pharmaceutical manufacturers remain at the Industry 2.0 stage, with only 20% having reached Industry 3.0, and even 10% still operating at the Industry 1.0 level. The foundation for digitalization and informatization in the pharmaceutical sector remains weak, indicating significant room for improvement in market penetration.

Mingdu Intelligent Cloud builds a "Pharmaceutical Smart Brain" grounded in R&D and manufacturing for the Pharma Industry 4.0 era, empowering every stage of development—including preclinical research, technology transfer, and commercial production. It has established a comprehensive product portfolio, providing end-to-end, one-stop digital solutions that cover the entire process of drug R&D, production, logistics, and quality management. Deeply rooted in the life sciences sector and driven by industrial R&D and technological innovation, Mingdu Intelligent Cloud actively addresses critical bottlenecks in the pharmaceutical industry. To date, it has secured over 250 independent intellectual property rights.

Mingdu Zhiyun builds a system covering laboratory process management, project management, resource management, and business management.“Mingdu Science Platform”——Mingdu Science Platform,Leveraging big data and cloud technologies, and featuring modules such as advanced R&D project management, electronic laboratory notebooks (ELN), research achievement registration management, laboratory material management, instrument and equipment management, and electronic regulatory submission management, this solution spans the entire lifecycle of drug development. It serves as an R&D accelerator for pharmaceutical companies, enhances compliance and quality assurance at the source, helps enterprises accumulate research achievements, and builds their core knowledge systems.

On the other side, Mingdu Intelligent Cloud has built“Mingdu Smart Manufacturing Integrated Platform”, an integrated smart factory digital platform tailored for GMP production scenarios in pharmaceutical enterprises. By leveraging automation, IoT, and visual monitoring technologies, it records production and testing process data in real time to ensure ongoing regulatory compliance throughout the manufacturing process. Through information systems such as Manufacturing Execution Systems (MES), Quality Control Laboratory Information Management Systems (QC LIMS), Warehouse Management Systems (WMS), and Quality Management Systems (QMS), it ensures compliant drug production, enhances pharmaceutical companies' quality assurance capabilities, and achieves full-process controllability and traceability.

To address the quality management needs of pharmaceutical companies, Mingdu Zhiyun providesOne-Stop Quality Management Solution, including a Document Management System (DMS), a Training Management System (TMS), and a Quality Process Management System (QMS). While providing customers with digital software services, it also disseminates advanced concepts for quality system development. The "Mingdu Quality Management Suite" integrates quality processes with key documents and training, helping pharmaceutical companies manage end-to-end traceability from the initiation of quality events to changes in controlled content, thereby resolving the challenge of balancing quality compliance with operational efficiency.

Mingdu Intelligent Cloud'sSmart Logistics SolutionsIt enables end-to-end digital management across warehousing, conveying, sorting, and software control, leveraging self-developed systems including Warehouse Management System (WMS), Warehouse Control System (WCS), Robot Control System (RCS), and digital twin technologies. By integrating in-plant logistics between warehousing and production, it optimizes information flow across production workshops and warehouses, reduces raw material waste, and enhances process control efficiency, thereby helping pharmaceutical companies achieve intensive, safe, and compliant logistics management.

Furthermore, in the digitalization sector of gene and cell therapy (CGT), Zhimi Technology, a subsidiary of Mingdu Intelligent Cloud, is dedicated to helping cell and gene therapy enterprises achieve full lifecycle digitalization spanning R&D, clinical trials, and commercial operations. Zhimi Technology’s digital products comply with the regulatory requirements of the NMPA, FDA, EMA, and other regulatory authorities. Its fully self-developed Personalized Treatment Integrated Management Platform (PTIMP) offers a comprehensive end-to-end digital solution. Zhimi Technology has established collaborations with dozens of emerging pharmaceutical companies specializing in vaccines, CAR-T therapies, monoclonal antibodies, and other areas, holding a leading market share among domestic cell therapy product manufacturers.

With the in-depth application of generative artificial intelligence (AIGC), Mingdu Zhiyun has taken the lead in launching “CHATCGT” within the industry—a regulatory chatbot designed for the cell and gene therapy (CGT) sector to address questions related to industry laws and regulations. Meanwhile, Mingdu Zhiyun has jointly established the Biopharmaceutical Artificial Intelligence Joint Laboratory with China Pharmaceutical University, actively leveraging cutting-edge technologies such as large language models, multimodal AI, AIGC, and machine learning to develop industry-specific solutions including intelligent pharmaceutical R&D assistants, Q&A bots, process optimization tools, and early warning systems for abnormal batches.

Mingdu Intelligent Cloud boasts a highly interdisciplinary team of experts with extensive industry experience, integrating IT (Information Technology), OT (Operational Technology), BT (Business Technology), and DT (Data Technology). The team brings together deep expertise and technical reserves across information technology, operations, business, and big data.

The company’s core team possesses profound understanding and practical experience in smart factories, the integration of informatization and industrialization, and the pharmaceutical industry, along with a global perspective. Technical personnel account for over 70% of the workforce, with expertise spanning multiple domains including pharmaceuticals, software/hardware, information security, artificial intelligence, big data, cloud computing, regulatory consulting, and validation services. This makes the team a rare asset in the industry, boasting a comprehensive service capability structure.

Under the leadership of its core team, Mingdu Zhiyun has achieved rapid growth. To date, the company has established its headquarters in Hangzhou, subsidiaries in Shanghai, Suzhou, and Wuhan, a branch in Beijing, and a service center in the Greater Bay Area. It has built a robust ecosystem centered on numerous benchmark cases with industry leaders, currently providing comprehensive services to over 350 clients, including super-large pharmaceutical groups, innovative drug companies, third-party CRO/CDMO service providers, and medical device manufacturers. Leveraging its unique pharmaceutical resources and ecological network, Mingdu Zhiyun has rapidly expanded its business globally, delivering efficient, high-quality services characterized by timely response and rapid deployment to global pharmaceutical industry clusters and markets. Furthermore, through its Quantum Innovation Field, the company is advancing the application of artificial intelligence in the industry, the establishment of industry standards, and the shared application of global data.

The pharmaceutical industry possesses unique characteristics, currently maintaining high growth rates alongside relatively low digital penetration. Given factors such as high technical barriers, substantial upfront investments, and long return cycles, the sector holds immense value for digital transformation. By establishing comprehensive digital solutions across drug R&D, manufacturing, traceability, and quality supervision, pharmaceutical companies can accelerate time-to-market and achieve efficient, lean, end-to-end digital management. This approach not only ensures drug quality and safety but also provides a robust foundation for safeguarding human health.

Mingdu Intelligent Cloud has developed end-to-end, full-stack solutions spanning the entire pharmaceutical lifecycle—from R&D and logistics to manufacturing and quality control. Its offerings cover a comprehensive portfolio of small molecules and large molecules, including chemical drugs, formulations, traditional Chinese medicines, and biologics, thereby providing customers with enhanced guarantees in productivity, safety, and sustainability. Looking ahead, Mingdu Intelligent Cloud will continue to uphold its mission of “safeguarding every medicine and protecting every patient,” collaborating with global pharmaceutical enterprises to advance the digital and intelligent transformation of the life sciences industry and lead the pharmaceutical sector toward substantial, high-impact upgrades.

SCGC Investment TeamIt was stated that as the pharmaceutical industry is one of the ten key sectors prioritized for intelligent upgrading in China, its further development has been constrained by limited overall digitalization and informatization management capabilities. Digital and intelligent transformation is therefore an inevitable path for the survival and growth of pharmaceutical enterprises. As a leader in the field of digital and intelligent services for life and health, Zhejiang Mingdu Intelligent Control Technology Co., Ltd. (Mingdu Zhiyun) has leveraged its profound understanding of the industry to build a comprehensive product suite covering the entire digital workflow of R&D, production, quality control, and logistics for pharmaceutical companies. Having successfully served numerous leading clients in the pharmaceutical sector, Mingdu Zhiyun’s strong product capabilities have gradually established its industry-leading position. Biopharmaceuticals have long been a key investment focus for Shenzhen Capital Group Co., Ltd. (SCGC), and we are highly optimistic about future opportunities in pharmaceutical digitalization. We look forward to partnering with Mingdu Zhiyun to address the digital needs of biopharmaceutical enterprises, seize opportunities presented by the digital economy, and support the digital transformation and upgrading of China’s pharmaceutical industry.

Huang Xiaohua, General Manager of China Merchants HealthIt was stated that the deep integration of technology and industry is a crucial pathway for China to address challenges, seize opportunities, and achieve high-quality development. As a rapidly evolving field in recent years, we believe that the convergence of life sciences and digital intelligence technologies harbors immense opportunities. China Merchants Health has consistently adhered to the development strategy of “hard tech + new business models,” focusing on frontier technological pharmaceuticals and high-end medical devices, with the aim of building a world-class platform for the life sciences industry. As a cornerstone project of China Merchants Health, Mingdu Intelligent Cloud (Zhejiang Mingdu Intelligent Control Technology Co., Ltd.) represents a vital component of China Merchants Health’s strategic investment layout in emerging industries. This additional investment follows China Merchants Group’s participation in two prior funding rounds for Mingdu. We will work closely with the Mingdu team to further deepen the integration of life sciences and digital intelligence technologies, strengthen product barriers through the application of new technologies, contribute to the sustainable development of the life and health industry in China and globally, and support Mingdu Intelligent Cloud in becoming a globally leading provider of digital-intelligence transformation services for the life sciences sector.

Wu Siqi, Managing Director of Index CapitalIt was stated that the pharmaceutical industry’s GDP output exceeds one trillion yuan, with the digital upgrading of the entire drug value chain facing a market opportunity worth hundreds of billions. This transformation not only meets pharmaceutical companies’ needs for cost reduction, efficiency improvement, and refined management but also ensures medication safety for a vast number of patients. As a leading domestic enterprise in pharmaceutical digitalization, Mingdu Intelligent Cloud boasts an exceptionally rare composite team integrating IT (Information Technology), OT (Operational Technology), BT (Biotechnology), and DT (Data Technology). The company has developed end-to-end, full-stack solutions covering the entire pharmaceutical lifecycle—from R&D, logistics, and production to quality management—empowering its pharmaceutical clients to build “digital laboratories” and “digital factories.” Index Capital remains firmly optimistic about the digitalization opportunities within the pharmaceutical sector and looks forward to continuing its partnership with Mingdu Intelligent Cloud to support the localization and digital upgrading of China’s pharmaceutical industry, ultimately benefiting more patients.

Shenzhen Capital Group Co., Ltd. is committed to its mission of discovering and empowering great enterprises, striving to be a discoverer and cultivator of innovative value. Since its establishment in 1999, SCGC has managed total assets exceeding RMB 470 billion, invested in more than 1,700 innovative high-tech enterprises, among which 263 have achieved public listings. Its portfolio spans industries such as information technology, biotechnology/health, new energy/energy conservation and environmental protection, new materials, intelligent manufacturing, internet, and consumer goods/modern services, covering the entire lifecycle of enterprises.

Established in 2018, the SCGC Hongtu Healthcare Industry Fund is the first healthcare industry fund launched by Shenzhen Capital Group Co., Ltd. (SCGC) as part of its “specialization” strategy. The fund focuses on identifying high-quality investment targets with strong innovation capabilities and significant growth potential to drive industrial development. It has invested in a portfolio of outstanding companies, including Akeso, RemeGen, YHLO, PolyMed, Laekna, GenFleet Therapeutics, Weilizhibo, Hannovue Medical, Mindray, and Themis Medical.

China Merchants Health Industry Holdings Co., Ltd. (hereinafter referred to as “China Merchants Health”) is a wholly-owned life science and technology industry development platform established by China Merchants Group. Guided by its vision and mission of “creating a healthy and better life for people through technological innovation,” China Merchants Health is committed to becoming an innovative health industry company with market influence, driven by the dual-engine model of “technological innovation + investment and operation.”